The association between type 2 diabetes disease trajectories and dementia incidence
Zimmerman, S. C.; Pacca, L.; Wells, W.; Ackley, S.; Glymour, M. M.
Show abstract
Introduction Type 2 diabetes (T2D) prevalence, severity, duration, and control are associated with dementia incidence, but prior literature is focused on specific pharmacologic, dietary, and exercise interventions in isolation while controlling for other co-occurring factors. Accounting for comprehensive life course experiences of the timing of diabetes onset, severity, treatment, and progression over a period of decades would provide a more comprehensive description of how life course diabetes progression and control is associated with dementia. Trajectories of diabetes diagnosis, pharmacological management, and disease progression are heterogeneous, and classifying these trajectories presents a significant methodological challenge. Methods Using deidentified survey and electronic health record data from Kaiser Permanente Northern California (KPNC) from the Research Program on Genes, Environment, and Health (RPGEH), we defined annual "states" for each eligible participant with T2D diagnosed between ages 50 and 70 based on KPNC, diabetes diagnosis, glycated hemoglobin, antidiabetes prescription count, and kidney dysfunction. We then employed sequence and cluster analyses to group participants into clusters with similar trajectories of these states. Finally, we estimated hazard ratios for incidence of Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) for each of these clusters as well as individuals with type 1 or other diabetes types, relative to participants without diabetes at age 70, using covariate-adjusted Cox proportional hazards models. Results Using the 18,688 participants with T2D included in the diabetes trajectory assessment, sequence and cluster analysis identified 9 clusters of T2D treatment and control histories between ages 50 and 70. Clusters differed markedly in timing of onset of T2D, glucose control, antidiabetes drug use and kidney function. Associations of these clusters with incident AD/ADRD after age 70 was heterogeneous and patterned by diabetes control and treatment history, particularly by diabetes duration and treatment regime. Conclusions In conclusion, in this real-world data context, we find increased diabetes severity, increased medication use, and faster progression to kidney disease is associated with increased risk of dementia. We find some patterns of diabetes severity and control are associated with greater dementia risk. This information may be useful in the context of targeted screening and allocation of preventative services for ADRD.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: an overview of the data from the epidemiological studies within the IMI DIRECT Consortium 92%
- Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomization study 91%
- Urinary metabolite profiling identifies biomarkers for risk of progression of diabetic nephropathy in 2,670 individuals with type 1 diabetes 91%
Similar papers in this journal
- Cognitive impairment at older ages among 8000 men and women living in Mexico City: cross-sectional analyses of a prospective study 92%
- Structural racism and COVID-19 response: Higher risk of exposure drives disparate COVID-19 deaths among Black and Hispanic/Latinx residents of Illinois, USA 89%
- Using the illness-death model to estimate age- and sex-standardized incidence rates of diabetes in Mexico from 2003 to 2015 89%
Similar papers in this journal
- Effects of Dipeptidyl Peptidase-4 Inhibitors and Sulfonylureas on Cognitive and Physical Function in Nursing Home Residents 92%
- Treatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population-based cohort study 92%
- Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network Study 91%
Similar papers in this journal
- Diabetes-related excess mortality in Mexico: a comparative analysis of national death registries between 2017-2019 and 2020 91%
- Metabolome-defined obesity and the risk of future diabetes and mortality 91%
- Accounting for age-related increases in HbA1c more accurately quantifies risk of Type 1 Diabetes progression in islet autoantibody-positive adults 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.